Type 2 diabetes mellitus augments Parkinson?s disease risk or the other way around: Facts, challenges and future possibilities

被引:11
作者
Faizan, Mohd [1 ,2 ]
Sarkar, Alika [1 ,2 ]
Singh, Mahendra Pratap [1 ,2 ,3 ]
机构
[1] Indian Inst Toxicol Res, Toxicogen & Predict Toxicol Lab, Syst Toxicol & Hlth Risk Assessment Grp, CSIR,IITR, 31 Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, Uttar Pradesh, India
[3] CSIR IITR, Toxicogen & Predict Toxicol Lab, Syst Toxicol & Hlth Risk Assessment Grp, Vishvigyan Bhawan, 31 Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India
关键词
T2DM; PD; Preclinical link; Clinical link; INSULIN-RESISTANCE; SUBSTANTIA-NIGRA; L-DOPA; MECHANISMS; GLUCOSE; BRAIN; HYPERGLYCEMIA; BROMOCRIPTINE; METABOLISM; THERAPY;
D O I
10.1016/j.arr.2022.101727
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
About 10% of the adult population is living with type 2 diabetes mellitus (T2DM) and 1% of the population over 60 years of age is suffering from Parkinson's disease (PD). A school of thought firmly believes that T2DM, an age -related disease, augments PD risk. Such relationship is reflected from the severity of PD symptoms in drug naive subjects possessing T2DM. Onset of Parkinsonian feature in case controls possessing T2DM corroborates the role of hyperglycemia in PD. A few cohort, meta-analysis and animal studies have shown an increased PD risk owing to insulin resistance. High fat diet and role of insulin signaling in the regulation of sugar metabolism, oxidative stress, alpha-synuclein aggregation and accumulation, inflammatory response and mitochondrial function in PD models and sporadic PD further connect the two. Although little is reported about the implication of PD in hyperglycemia and T2DM, a few studies have also contradicted. Ameliorative effect of anti-diabetic drugs on Parkinsonian symptoms and vague outcome of anti-PD medications in T2DM patients also suggest a link. The article reviews the literature supporting augmented risk of one by the other, analysis of proof of the concept, facts, challenges, future possibilities and standpoint on the subject.
引用
收藏
页数:13
相关论文
共 128 条
  • [1] Aksoy D, 2017, AM J MED SCI, V354, P319, DOI 10.1016/j.amjms.2017.05.002
  • [2] Parkinson's Disease, Diabetes and Cognitive Impairment
    Ashraghi, Mohammad R.
    Pagano, Gennaro
    Polychronis, Sotirios
    Niccolini, Flavia
    Politis, Marios
    [J]. RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2016, 10 (01) : 11 - 21
  • [3] Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors
    Aslanoglou, Despoina
    Bertera, Suzanne
    Sanchez-Soto, Marta
    Free, R. Benjamin
    Lee, Jeongkyung
    Zong, Wei
    Xue, Xiangning
    Shrestha, Shristi
    Brissova, Marcela
    Logan, Ryan W.
    Wollheim, Claes B.
    Trucco, Massimo
    Yechoor, Vijay K.
    Sibley, David R.
    Bottino, Rita
    Freyberg, Zachary
    [J]. TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)
  • [4] The Impact of Type 2 Diabetes in Parkinson's Disease
    Athauda, Dilan
    Evans, James
    Wernick, Anna
    Virdi, Gurvir
    Choi, Minee L.
    Lawton, Michael
    Vijiaratnam, Nirosen
    Girges, Christine
    Ben-Shlomo, Yoav
    Ismail, Khalida
    Morris, Huw
    Grosset, Donald
    Foltynie, Thomas
    Gandhi, Sonia
    [J]. MOVEMENT DISORDERS, 2022, 37 (08) : 1612 - 1623
  • [5] Exenatide and the treatment of patients with Parkinson's disease
    Aviles-Olmos, Iciar
    Dickson, John
    Kefalopoulou, Zinovia
    Djamshidian, Atbin
    Ell, Peter
    Soderlund, Therese
    Whitton, Peter
    Wyse, Richard
    Isaacs, Tom
    Lees, Andrew
    Limousin, Patricia
    Foltynie, Thomas
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06) : 2730 - 2736
  • [6] Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease
    Badawi, Ghada A.
    Abd El Fattah, Mai A.
    Zaki, Hala F.
    El Sayed, Moushira I.
    [J]. INFLAMMOPHARMACOLOGY, 2017, 25 (03) : 369 - 382
  • [7] L-DOPA AND STREPTOZOTOCIN-INDUCED DIABETIC NEPHROPATHY IN RATS
    BARTHELMEBS, M
    VAILLY, B
    VELLY, J
    GRIMA, M
    IMBS, JL
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1990, 3 (06) : S72 - S74
  • [8] Impaired brain insulin signalling in Parkinson's disease
    Bassil, Fares
    Delamarre, Anna
    Canron, Marie-Helene
    Dutheil, Nathalie
    Vital, Anne
    Negrier-Leibreich, Marie-Laure
    Bezard, Erwan
    Fernagut, Pierre-Olivier
    Meissner, Wassilios G.
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2022, 48 (01)
  • [9] Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease
    Bohnen, Nicolaas I.
    Kotagal, Vikas
    Mueller, Martijn L. T. M.
    Koeppe, Robert A.
    Scott, Peter J. H.
    Albin, Roger L.
    Frey, Kirk A.
    Petrou, Myria
    [J]. PARKINSONISM & RELATED DISORDERS, 2014, 20 (12) : 1394 - 1398
  • [10] ENDOCRINE FUNCTION AND GLUCOSE METABOLISM IN PATIENTS WITH PARKINSONS DISEASE AND THEIR ALTERATION BY L-DOPA
    BOYD, AE
    LEBOVITZ, HE
    FELDMAN, JM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1971, 33 (05) : 829 - +